Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Wednesday, July 19, 2017

Quarter of MS Patients in UK Not Aware of Disease-modifying Treatments, Online Survey Reports

Click here to receive MS news via e-mail

A recent patient survey reveals that almost one in four people with multiple sclerosis in the U.K. are not aware of available treatments that could help delay the onset of disability, even though a clear majority put disability as a chief worry.
The report, funded by Sanofi Genzyme, was conducted by Adelphi Research UK via online questionnaires given 100 healthcare specialists, including neurologists, and 120 patients with all types of multiple sclerosis in 2016. Called “The Missing Pieces,” it reports that 83 percent of relapsing-remitting MS patients ranked preventing progression and disability as their primary concern.  However, 24 percent of those who took part in the survey reported not being aware of treatments that might work to delay MS onset and progressive loss of function.
Only 21 percent of MS patients said they were actually receiving disease-modifying treatments (DMTs), potentially one of the lowest rates in Europe.
Respondents were from England (85 percent), Scotland (7 percent), Wales (7 percent), and Northern Ireland (1 percent), and included RRMSpatients as well as those with secondary progressive and primary progressive MS.
“It  is  essential  that  treatments  are considered in  a  timely  manner  to  increase  the  likelihood  of preventing  long-term  disability  and  ultimately  to  decrease  the  chance  of  MS  impacting  day-to-day quality of life,” Emma Matthews, MS Nurse Specialist at Northampton General Hospital, said in a release published by Sanofi on a company website.

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 
Join us, opt-in here: 

No comments: